Filoviruses and arenaviruses are two major families of lethal hemorrhagic fever viruses for which no vaccines or treatments are currently available. Previous work by several investigators involved in this proposal has unequivocally demonstrated the feasibility of protecting non-human primates against viral challenge with immunotherapy. This highly translational proposal will identify the most effective monoclonal antibodies and from them, create broad-spectrum antibody cocktails for pre- or post-exposure use. To achieve this goal, we will leverage the consortium's large collection of anti-filovirus and anti-arenavirus antibodies, as well as new antibodies to be derived from ongoing and proposed discovery efforts. However, it will not be feasible to test each of our hundreds of candidate antibodies and thousands of potential antibody combinations in animals without some initial in vitro downselection. To generate a manageable set of candidate antibodies and cocktails, Core C (working together the three project teams and the Gore D team) will categorize antibodies into structural and functional groups, perform rules-based triage of antibody candidates, and design antibody cocktails based on antiviral activity and functional diversity. Finally and importantly. Core C will prioritize candidate cocktails based on their susceptibility to escape mutations, and will, together with Core D, identify antibodies most resistant to escape, as well as replacement antibodies that will """"""""mop up"""""""" escaping virions. In addition to selection of the most effective single antibodies and cocktails of antibodies to forward for patient use, this Gore will provide essential information that addresses major, basic knowledge gaps in the field. Our comprehensive analysis will illustrate which epitopes lead to the most effective protection, which in vitro assays are the best predictors of in vivo efficacy, and which epitopes lead to broad-spectrum reactivity and protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109762-01
Application #
8654214
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
2014-03-15
Project End
2019-02-28
Budget Start
2014-03-15
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$761,167
Indirect Cost
$105,104
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Liu, Guodong; Wong, Gary; Su, Shuo et al. (2017) Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol Med 23:820-830
Wong, Gary; Mendoza, Emelissa J; Plummer, Francis A et al. (2017) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther :1-15
Hofmann, Daniel; Lai, Jonathan R (2017) Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level. Clin Vaccine Immunol 24:
Nyakatura, Elisabeth K; Soare, Alexandra Y; Lai, Jonathan R (2017) Bispecific antibodies for viral immunotherapy. Hum Vaccin Immunother 13:836-842
Zhao, Xuelian; Howell, Katie A; He, Shihua et al. (2017) Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 169:891-904.e15
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
He, Jing; Melnik, Lilia I; Komin, Alexander et al. (2017) Ebola Virus Delta Peptide is a Viroporin. J Virol :
Fausther-Bovendo, H; Qiu, X; McCorrister, S et al. (2017) Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 7:42147
Wec, Anna Z; Herbert, Andrew S; Murin, Charles D et al. (2017) Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell 169:878-890.e15
Kroeker, Andrea; He, Shihua; de La Vega, Marc-Antoine et al. (2017) Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8:46262-46272

Showing the most recent 10 out of 42 publications